ZA200807380B - 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists - Google Patents
2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonistsInfo
- Publication number
- ZA200807380B ZA200807380B ZA200807380A ZA200807380A ZA200807380B ZA 200807380 B ZA200807380 B ZA 200807380B ZA 200807380 A ZA200807380 A ZA 200807380A ZA 200807380 A ZA200807380 A ZA 200807380A ZA 200807380 B ZA200807380 B ZA 200807380B
- Authority
- ZA
- South Africa
- Prior art keywords
- prostaglandin
- pyrimidine
- substituted
- receptor antagonists
- monosubstituted amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74467606P | 2006-04-12 | 2006-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200807380B true ZA200807380B (en) | 2009-05-27 |
Family
ID=38294040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200807380A ZA200807380B (en) | 2006-04-12 | 2008-08-27 | 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists |
Country Status (26)
Country | Link |
---|---|
US (1) | US20090036469A1 (xx) |
EP (1) | EP2010503A1 (xx) |
JP (1) | JP2009533473A (xx) |
KR (1) | KR20080108287A (xx) |
CN (1) | CN101421252B (xx) |
AR (1) | AR060403A1 (xx) |
AU (1) | AU2007238052B2 (xx) |
BR (1) | BRPI0710710A2 (xx) |
CA (1) | CA2649083C (xx) |
CR (1) | CR10249A (xx) |
DO (1) | DOP2007000068A (xx) |
EC (1) | ECSP088813A (xx) |
HK (1) | HK1131975A1 (xx) |
HN (1) | HN2008001530A (xx) |
MA (1) | MA30409B1 (xx) |
MX (1) | MX2008011369A (xx) |
NO (1) | NO20084291L (xx) |
NZ (1) | NZ571793A (xx) |
PE (1) | PE20080186A1 (xx) |
RU (1) | RU2431631C2 (xx) |
TN (1) | TNSN08339A1 (xx) |
TW (1) | TW200815395A (xx) |
UA (1) | UA95950C2 (xx) |
UY (1) | UY30283A1 (xx) |
WO (1) | WO2007121280A1 (xx) |
ZA (1) | ZA200807380B (xx) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5039594B2 (ja) * | 2008-02-08 | 2012-10-03 | 株式会社日立ハイテクノロジーズ | レビュー装置,検査領域設定支援システム、および、欠陥の画像得方法 |
AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
WO2011115940A1 (en) * | 2010-03-16 | 2011-09-22 | Aventis Pharmaceuticals Inc. | Substituted pyrimidines as prostaglandin d2 receptor antagonists |
TW201204708A (en) * | 2010-03-16 | 2012-02-01 | Aventis Pharma Inc | A substituted pyrimidine as a prostaglandin D2 receptor antagonist |
BR112013000254A2 (pt) | 2010-07-05 | 2016-05-24 | Actelion Pharmaceuticals Ltd | derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2 |
EP2621276B1 (en) * | 2010-09-30 | 2017-12-27 | Merck Sharp & Dohme Corp. | 2-alkoxy pyrimidine pde10 inhibitors |
CN104011021B (zh) | 2011-12-21 | 2016-08-24 | 埃科特莱茵药品有限公司 | 杂环衍生物及其作为***素d2受体调节剂的用途 |
WO2014006585A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
EP3382391A1 (en) | 2012-10-24 | 2018-10-03 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
CN105745198B (zh) * | 2013-11-08 | 2018-09-21 | 橘生药品工业株式会社 | 羧甲基哌啶衍生物 |
RS63190B1 (sr) | 2014-08-04 | 2022-06-30 | Nuevolution As | Opciono fuzionisani derivati pirimidina zamenjeni heterociklilom korisni za lečenje zapaljenskih, metaboličkih, onkoloških i autoimunskih bolesti |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Pge2レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
PE20191811A1 (es) | 2017-05-18 | 2019-12-26 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
KR102632028B1 (ko) | 2017-05-18 | 2024-01-31 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 페닐 유도체 |
SG11202002065VA (en) | 2017-09-13 | 2020-04-29 | Progenity Inc | Preeclampsia biomarkers and related systems and methods |
EP4029380A4 (en) * | 2019-09-13 | 2023-09-13 | Meiji Co., Ltd | SOLID FOOD, AND SOLID MILK |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
EP4126875A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3644799A1 (de) * | 1986-06-04 | 1987-12-10 | Hoechst Ag | Neue pyrimidin-derivate, deren herstellung und verwendung |
SE0200411D0 (sv) * | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
GT200500284A (es) * | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
GT200600457A (es) * | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 |
-
2007
- 2007-04-10 AR ARP070101501A patent/AR060403A1/es not_active Application Discontinuation
- 2007-04-10 DO DO2007000068A patent/DOP2007000068A/es unknown
- 2007-04-12 MX MX2008011369A patent/MX2008011369A/es active IP Right Grant
- 2007-04-12 TW TW096112790A patent/TW200815395A/zh unknown
- 2007-04-12 KR KR1020087024764A patent/KR20080108287A/ko not_active Application Discontinuation
- 2007-04-12 UA UAA200813109A patent/UA95950C2/ru unknown
- 2007-04-12 JP JP2009505615A patent/JP2009533473A/ja not_active Abandoned
- 2007-04-12 BR BRPI0710710-2A patent/BRPI0710710A2/pt not_active IP Right Cessation
- 2007-04-12 NZ NZ571793A patent/NZ571793A/en not_active IP Right Cessation
- 2007-04-12 CA CA2649083A patent/CA2649083C/en not_active Expired - Fee Related
- 2007-04-12 EP EP07760526A patent/EP2010503A1/en not_active Withdrawn
- 2007-04-12 RU RU2008144578/04A patent/RU2431631C2/ru not_active IP Right Cessation
- 2007-04-12 UY UY30283A patent/UY30283A1/es not_active Application Discontinuation
- 2007-04-12 AU AU2007238052A patent/AU2007238052B2/en not_active Expired - Fee Related
- 2007-04-12 PE PE2007000450A patent/PE20080186A1/es not_active Application Discontinuation
- 2007-04-12 WO PCT/US2007/066481 patent/WO2007121280A1/en active Application Filing
- 2007-04-12 CN CN2007800127354A patent/CN101421252B/zh not_active Expired - Fee Related
-
2008
- 2008-08-26 CR CR10249A patent/CR10249A/es not_active Application Discontinuation
- 2008-08-27 ZA ZA200807380A patent/ZA200807380B/xx unknown
- 2008-08-27 TN TNP2008000339A patent/TNSN08339A1/en unknown
- 2008-10-07 US US12/246,918 patent/US20090036469A1/en not_active Abandoned
- 2008-10-09 EC EC2008008813A patent/ECSP088813A/es unknown
- 2008-10-10 HN HN2008001530A patent/HN2008001530A/es unknown
- 2008-10-14 NO NO20084291A patent/NO20084291L/no not_active Application Discontinuation
- 2008-11-10 MA MA31375A patent/MA30409B1/fr unknown
-
2009
- 2009-10-28 HK HK09110008.0A patent/HK1131975A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HN2008001530A (es) | 2012-01-17 |
NO20084291L (no) | 2008-11-11 |
HK1131975A1 (en) | 2010-02-12 |
BRPI0710710A2 (pt) | 2011-08-16 |
AR060403A1 (es) | 2008-06-11 |
RU2008144578A (ru) | 2010-05-20 |
DOP2007000068A (es) | 2007-10-31 |
CN101421252A (zh) | 2009-04-29 |
US20090036469A1 (en) | 2009-02-05 |
MA30409B1 (fr) | 2009-05-04 |
EP2010503A1 (en) | 2009-01-07 |
KR20080108287A (ko) | 2008-12-12 |
ECSP088813A (es) | 2008-11-27 |
UY30283A1 (es) | 2007-11-30 |
PE20080186A1 (es) | 2008-04-15 |
CN101421252B (zh) | 2011-10-12 |
AU2007238052B2 (en) | 2011-12-22 |
TW200815395A (en) | 2008-04-01 |
WO2007121280A1 (en) | 2007-10-25 |
UA95950C2 (xx) | 2011-09-26 |
MX2008011369A (es) | 2008-09-18 |
CR10249A (es) | 2008-11-26 |
CA2649083A1 (en) | 2007-10-25 |
AU2007238052A1 (en) | 2007-10-25 |
CA2649083C (en) | 2011-06-28 |
TNSN08339A1 (en) | 2009-12-29 |
JP2009533473A (ja) | 2009-09-17 |
RU2431631C2 (ru) | 2011-10-20 |
NZ571793A (en) | 2011-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1131975A1 (en) | 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists | |
TWI372751B (en) | Pyrimidines as prostaglandin d2 receptor antagonists | |
IL184816A0 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
IL196587A0 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
EP2099454A4 (en) | AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS | |
ZA201001597B (en) | Octahydropentalene compounds as chemokine receptor antagonists | |
IL198825A0 (en) | Substituted diazepan compounds as orexin receptor antagonists | |
EP2058304A4 (en) | P2X4 RECEPTOR ANTAGONIST | |
SI2094690T1 (sl) | Derivati 2-aza-biciklo(3.1.0)heksana kot antagonisti receptorja za oreksin | |
ZA200800320B (en) | Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists | |
EP2184278A4 (en) | P2X4 RECEIVER ANTAGONIST | |
ZA200903334B (en) | Substituted diazepan compounds as orexin receptor antagonists | |
EP2325175A4 (en) | 2,4-DIAMINOPYRIMIDINVERBINDUNG | |
IL190686A0 (en) | Il-21 receptor antagonists | |
EP2170064A4 (en) | 6,5-pyrrolopiperidine tachykinin receptor antagonists | |
IL198542A0 (en) | 2-aminoquinolines as 5-ht(5a)receptor antagonists | |
ZA201005179B (en) | 4-aminopyrimidine derivatives as histamine h4 receptor antagonists | |
EP2120564A4 (en) | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | |
ZA200903499B (en) | Indoles which act as via receptor antagonists | |
ZA200802339B (en) | Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists | |
AP2008004687A0 (en) | Insecticidal methods using 4-amino-5-chloro-thieno(2,3-d)-pyrimidine compounds | |
EP2222676A4 (en) | A1-adenosine receptor antagonistic | |
IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists | |
ZA200810564B (en) | 2-phenyl-indoles as prostaglandin D2 receptor antagonists | |
GB0525029D0 (en) | Receptor Antagonist |